The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Second-line FOLFOX chemotherapy in patients with metastatic gallbladder cancer and cholangiocarcinoma.
Jose Luis Leal
No relevant relationships to disclose
Juan Carlos Roa
No relevant relationships to disclose
Nicolas Jarufe
No relevant relationships to disclose
Jorge Madrid
No relevant relationships to disclose
Carolina Ibanez
No relevant relationships to disclose
Maria Elisa Herrera
No relevant relationships to disclose
Marcelo Garrido
No relevant relationships to disclose
Bruno Nervi
No relevant relationships to disclose